Erlotinib is a tyrosine kinase inhibitor recently approved by the Food and Drug
Administration for the treatment of non–small-cell lung cancer and pancreatic cancer. We …

We describe the case of a never-smoker who received second-line erlotinib as a treatment
for his non-small cell lung cancer. Within one month, acute hepatic failure developed as well …

Lung cancer is the second-most common cancer in men and women, accounting for about
13% of all diagnosed cancers. It is, however, the leading cause of cancer-related deaths in …

Background: Erlotinib is an oral, small-molecule targeting therapy which inhibits epidermal
growth factor tyrosine kinase receptors. Erlotinib has been administered for the treatment of …

INTRODUCTION: Hepatotoxicity secondary to gefitinib, an oral tyrosine kinase inhibitor (TKI)
against the epidermal growth factor receptor (EGFR), is under-appreciated, even though it …

A 66-year-old nonsmoking woman presented with enlarged left supraclavicular lymph
nodes. She had no history of liver disease, alcohol intake, or hepatitis. Baseline blood tests …

Objective: To report a case of erlotinib-induced hepatitis complicated by fatal lactic acidosis
in an elderly patient with lung adenocarcinoma and diabetes mellitus. Case Summary: A 77 …

There have been constant debates regarding the issues of chemotherapy use and dosing in
setting of liver insufficiency in patients with solid malignancies. Many chemotherapeutic …

Erlotinib is an orally available, reversible tyrosine kinase inhibitor of the epidermal growth
factor receptor. Encouraging activity as a single agent and in combination with other …

With the increased use of tyrosine kinase inhibitors as successful therapy in selected
malignancies, their adverse effects will grow, especially when combination therapy is used …